WebSep 30, 2024 · Cholangiocarcinoma (CCA) is a lethal malignancy in the hepatobiliary system, with dysregulated protein expression and phosphorylation signaling. However, the protein and phosphorylation signatures of CCAs are little-known. Here, we performed the proteomic and phosphoproteomic profiling of tumors and normal adjacent tissues (NATs) … WebJul 23, 2024 · Cholangiocarcinoma (CCA) is a primary malignancy of the biliary tract with a dismal prognosis. Recently, several actionable genetic aberrations were identified with significant enrichment in...
Factsheets on Biomarkers OncologyPRO - ESMO
WebJun 13, 2024 · The promising results of pemigatinib and infigratinib in advanced unresectable cholangiocarcinoma harboring FGFR2fusions or rearrangement, and erdafitinib in metastatic urothelial carcinoma with FGFR2and FGFR3genetic aberrations, lead to their accelerated approval by the United States (USA) FDA. WebBy finding that a patient with cholangiocarcinoma harbored both a unique FGFR2-TDRD1 (tudor domain-containing 1) fusion and tumor infiltrating T lymphocytes that recognized it in a specific manner, this study demonstrates that FGFR2 fusions can be immunogenic. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY ruban led adhesif
FGFR inhibitors for advanced cholangiocarcinoma - The Lancet
WebApr 14, 2024 · Abstract. Background: Fibroblast growth factor receptor (FGFR) alterations are promising targets in different tumors. We report results of FIGHT-207, an open-label, single-arm phase 2 study of pemigatinib, a potent, selective FGFR1-3 inhibitor, in … WebJul 10, 2024 · As recent as April of this year, there was an FDA approval of a pan-FGFR1, FGFR2, and FGFR3 inhibitor, pemigatinib. The drug’s approval was based on a trial … WebNov 23, 2024 · RLY-4008, a highly selective FGFR2 inhibitor, has demonstrated promising efficacy in patients with FGFR2 -altered cholangiocarcinoma, while sparing patients the adverse effects (AEs)... ruban led baltimore